{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/160541825"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "the potential that earlier clinical trials may not be predictive of future results in the Contrave outcomes trial; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexig" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "prnewswire.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/417949584"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/160541825"] } } }
